Alchem Laboratories Corporation

Dedicated to excellence in custom synthesis

Alchem awarded 5-year Contract for "CRO Support for NCATS Medicinal Chemistry for Lead Optimization"

The Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development. The objective of this contract is to support the DPI drug development programs by identifying preclinical drug candidates with improved efficacy, optimized ADME properties, and minimal predicted toxicity. One of the DPI program requirements is to efficiently identify preclinical development candidates for rare and neglected diseases. To accomplish this endeavor, DPI has a need for a team of chemists; pharmacologists; absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetics (PK) experts; and toxicologists working closely together to perform medicinal chemistry lead optimization.

While this Contract will be primarily in support of the DPI drug development programs. The Government reserves the right to allow other drug development programs at NIH to solicit task order proposals. As such, this Contract is not limited to rare or neglected disorders. Contract Award Dollar Amount: $17,887,012.